Fifth Lane Capital’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Fifth Lane Capital’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-50,000	Closed	-$92.5K	–	275
2023 Q1	$92.5K	Buy	+50,000	New	+$61.9K	0.05%	78

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Fifth Lane Capital's JNCE Position: Q2 2023 in Review

Fifth Lane Capital sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 50,000 shares — an estimated $92.5K sold.

Fifth Lane Capital first reported a position in JNCE in Q1 2023 and held it in 1 quarter. The position peaked at $92.5K in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Fifth Lane Capital reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Fifth Lane Capital sold 50,000 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $92.5K.
Fifth Lane Capital first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Fifth Lane Capital's Jounce Therapeutics, Inc. Common Stock position peaked at $92.5K in Q1 2023.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Fifth Lane Capital's 13F filing for Q2 2023, filed 3 Aug 2023.